---
figid: PMC8296533__40364_2021_312_Fig1_HTML
figtitle: Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
organisms:
- Homo sapiens
- Mus musculus
- Carpinus caroliniana
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8296533
filename: 40364_2021_312_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8296533/figure/Fig1/
number: F1
caption: Abnormal tumor vasculature triggers immunosuppression in the tumor microenvironment
  (created with BioRender.com). Malformed and dysfunctional vascular systems in breast
  cancer cause perfusion restriction, leading to hypoxia and acidosis in the TME.
  Tumor vasculature abnormalities promote immunosuppression through multiple mechanisms.
  VEGF induces tumor angiogenesis, and tumor vascular endothelial cells with PD-L1
  and Fas-L expression recruit immunosuppressive cells. CSF1, TGF-β, and CXCL12 polarize
  TAMs from a protumorigenic M1-like phenotype into an antitumorigenic M2-like phenotype.
  VEGF, CXCL8, and CXCL12 inhibit DC maturation, resulting in impaired antigen presentation
  and leading to disrupted T cell activation. TGF-β and IL-10 induce CD8+ T cell exhaustion,
  and TGF-β inhibits NK cell function. Tregs and MDSCs accumulate, activate, and expand
  in the TME. The CAFs in the TME promote tumor angiogenesis by producing VEGF, PDGF-c,
  PDPN, and MMP13. The PD-L1 pathway is normally activated as a mechanism to evade
  the antitumor immune response. Overall, aberrant tumor angiogenesis results in an
  immunosuppressive TME. ANG2, Angiopoietin 2; CAFs, Cancer-associated fibroblast;
  CCL28, CC chemokine ligand 28; CXCL8, CXC chemokine ligand 8; CXCL12, CXC chemokine
  ligand 12; CSF1, Colony-stimulating factor 1; DC, Dendritic cell; Fas-L, FAS antigen
  ligand; FGF, Fibroblast growth factor; MMP, Matrix metallopeptidase; NK, Natural
  killer; PD-1, Programmed cell death protein 1; PD-L1, Programmed cell death 1 ligand
  1; PDGF, Platelet-derived growth factor; PDPN, Podoplanin; ROS, Reactive oxygen
  species; TAM, Tumor-associated macrophage; TGF-β, Transforming growth factor beta;
  TME, Tumor microenvironment; Tregs, Regulatory T cells; VEGF, Vascular endothelial
  growth factor
papertitle: Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
reftext: Wuzhen Chen, et al. Biomark Res. 2021;9:59.
year: '2021'
doi: 10.1186/s40364-021-00312-w
journal_title: Biomarker Research
journal_nlm_ta: Biomark Res
publisher_name: BioMed Central
keywords: Antiangiogenic therapy | Immunotherapy | Breast cancer | Tumor microenvironment
  (TME)
automl_pathway: 0.8487357
figid_alias: PMC8296533__F1
figtype: Figure
redirect_from: /figures/PMC8296533__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8296533__40364_2021_312_Fig1_HTML.html
  '@type': Dataset
  description: Abnormal tumor vasculature triggers immunosuppression in the tumor
    microenvironment (created with BioRender.com). Malformed and dysfunctional vascular
    systems in breast cancer cause perfusion restriction, leading to hypoxia and acidosis
    in the TME. Tumor vasculature abnormalities promote immunosuppression through
    multiple mechanisms. VEGF induces tumor angiogenesis, and tumor vascular endothelial
    cells with PD-L1 and Fas-L expression recruit immunosuppressive cells. CSF1, TGF-β,
    and CXCL12 polarize TAMs from a protumorigenic M1-like phenotype into an antitumorigenic
    M2-like phenotype. VEGF, CXCL8, and CXCL12 inhibit DC maturation, resulting in
    impaired antigen presentation and leading to disrupted T cell activation. TGF-β
    and IL-10 induce CD8+ T cell exhaustion, and TGF-β inhibits NK cell function.
    Tregs and MDSCs accumulate, activate, and expand in the TME. The CAFs in the TME
    promote tumor angiogenesis by producing VEGF, PDGF-c, PDPN, and MMP13. The PD-L1
    pathway is normally activated as a mechanism to evade the antitumor immune response.
    Overall, aberrant tumor angiogenesis results in an immunosuppressive TME. ANG2,
    Angiopoietin 2; CAFs, Cancer-associated fibroblast; CCL28, CC chemokine ligand
    28; CXCL8, CXC chemokine ligand 8; CXCL12, CXC chemokine ligand 12; CSF1, Colony-stimulating
    factor 1; DC, Dendritic cell; Fas-L, FAS antigen ligand; FGF, Fibroblast growth
    factor; MMP, Matrix metallopeptidase; NK, Natural killer; PD-1, Programmed cell
    death protein 1; PD-L1, Programmed cell death 1 ligand 1; PDGF, Platelet-derived
    growth factor; PDPN, Podoplanin; ROS, Reactive oxygen species; TAM, Tumor-associated
    macrophage; TGF-β, Transforming growth factor beta; TME, Tumor microenvironment;
    Tregs, Regulatory T cells; VEGF, Vascular endothelial growth factor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Vegfa
  - Ang2
  - Angpt2
  - Csf1
  - Cxcl12
  - Pdgfb
  - Spp1
  - Cd274
  - Fasl
  - Pdcd1
  - Fgf2
  - Ccl28
  - Pdgfc
  - Pdpn
  - Mmp13
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - ANGPT2
  - VPS51
  - CSF1
  - CXCL12
  - PDGFB
  - SPP1
  - CD8A
  - CD8B
  - CD274
  - FASLG
  - FAS
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - FGF2
  - FGF13
  - CCL28
  - ENC1
  - SETD2
  - TBX1
  - PDPN
  - PDGFC
  - MMP13
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - op
  - fo
  - et
  - Fas1
  - FASN1
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - bnl
  - tgo
  - sima
  - fl
---
